Free Trial
→ There’s a new type of capitalism (From Porter & Company) (Ad)tc pixel
NASDAQ:RAPT

Rapt Therapeutics Q3 2025 Earnings Report

Rapt Therapeutics logo
ProfileEarnings HistoryForecast

Rapt Therapeutics EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.88
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

Rapt Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rapt Therapeutics Announcement Details

Quarter
Q3 2025
Date
11/6/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Rapt Therapeutics' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Rapt Therapeutics' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Rapt Therapeutics Earnings Headlines

This Biotech Was Quietly Bought Before a $58 Per Share Takeout
March 21, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/03/21/this-biotech-was-quietly-bought-before-a-usd58-per-share-takeout/
RAPT Therapeutics Completes Acquisition and Transitions to Private Ownership
March 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RAPT/pressreleases/560703/rapt-therapeutics-completes-acquisition-and-transitions-to-private-ownership/
There’s a new type of capitalism
The U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghouse, MP Materials, Lithium Americas, and others - plus roughly $2 billion in quantum computing investments. When these deals were announced, the stocks soared overnight. Porter Stansberry, founder of one of the world's largest financial research firms, says this shift away from free-market capitalism is the most consequential economic story in centuries - and almost no one is prepared for it. He's identified the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this new reality.tc pixel
June 14 at 1:00 AM  |  Porter & Company (Ad)
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
March 15, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/03/15/this-investor-built-a-usd56-million-position-in-rapt-last-quarter-it-was-just-acquired-for-usd58-per-share/
GSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth Story
March 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/gsk-rapt-acquisition-adds-food-180655656.html
GSK reached out to buyout target's big shareholder before talking to senior leaders
March 5, 2026  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2026/03/05/food-allergies-gsk-rapt-ozureprubart-jpm.html
See More Rapt Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rapt Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapt Therapeutics and other key companies, straight to your email.

About Rapt Therapeutics

Rapt Therapeutics (NASDAQ:RAPT), Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. By selectively blocking CCR4-mediated migration of pathogenic T cells to inflamed tissues, RPT193 aims to reduce disease activity without broad immunosuppression. RAPT is also advancing discovery-stage programs against additional chemokine receptors involved in tissue inflammation, including efforts in ulcerative colitis and other indications.

Since its initial public offering in 2020, RAPT has expanded its operations across the United States, leveraging partnerships and collaborations to extend its global reach. The company maintains research and development facilities in San Diego and engages with clinical sites worldwide to advance its pipeline.

Under the leadership of Chief Executive Officer John C. Huggins, RAPT’s management team brings extensive experience in immunology, drug discovery and clinical development. The organization is guided by a board of directors and scientific advisors with deep expertise in translational research and biopharmaceutical innovation.

View Rapt Therapeutics Profile
Earnings Tools